ELVN vs. ETNB, TNGX, ARQT, SAGE, IMNM, SPRY, ZNTL, OPK, ALXO, and LBPH
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include 89bio (ETNB), Tango Therapeutics (TNGX), Arcutis Biotherapeutics (ARQT), Sage Therapeutics (SAGE), Immunome (IMNM), ARS Pharmaceuticals (SPRY), Zentalis Pharmaceuticals (ZNTL), OPKO Health (OPK), ALX Oncology (ALXO), and Longboard Pharmaceuticals (LBPH). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
89bio received 91 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 62.09% of users gave 89bio an outperform vote.
95.1% of Enliven Therapeutics shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 45.8% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Enliven Therapeutics had 8 more articles in the media than 89bio. MarketBeat recorded 11 mentions for Enliven Therapeutics and 3 mentions for 89bio. Enliven Therapeutics' average media sentiment score of 0.95 beat 89bio's score of 0.65 indicating that 89bio is being referred to more favorably in the media.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
89bio presently has a consensus target price of $29.00, indicating a potential upside of 221.15%. Enliven Therapeutics has a consensus target price of $34.00, indicating a potential upside of 38.83%. Given Enliven Therapeutics' higher possible upside, research analysts clearly believe 89bio is more favorable than Enliven Therapeutics.
89bio's return on equity of -26.56% beat Enliven Therapeutics' return on equity.
89bio has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Summary
Enliven Therapeutics beats 89bio on 8 of the 15 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
